Oncology & Biosimilars To Be Growth Engines For Pfizer

Pfizer reported its Q2 results on Tuesday, August 2th, with 11% increase in revenue and 14% increase in EPS as compared to last year. We believe oncology and biosimilars to be growth engines for Pfizer in coming quarters. The oncology division should grow due to its flagship drug Ibance and strong phase 3 pipeline. In addition, Pfizer could grow its legacy business by depending on biosimilars. The approval of first biosimilar in the U.S., Zarxio, opened up new opportunities for biosimilar develo...